Loading clinical trials...
Loading clinical trials...
A Multi-center, Randomized, Double-blind, Parallel-group Vehicle and Active Controlled Study to Compare the Efficacy and Safety of CD0271 0.3% / CD1579 2.5% Topical Gel Versus Topical Gel Vehicle in Subjects With Acne Vulgaris
Conditions
Interventions
CD0271 0.3% / CD1579 2.5%
CD0271 0.1% / CD1579 2.5%
+1 more
Locations
31
United States
Galderma Investigational site
Birmingham, Alabama, United States
Galderma Investigationnal Site
Mobile, Alabama, United States
Galderma investigational Site
Hot Springs, Arkansas, United States
Galderma Investigational Site
Los Angeles, California, United States
Galderma Investigational Site
Sacramento, California, United States
Galderma Investigational Site
Santa Monica, California, United States
Start Date
July 1, 2013
Primary Completion Date
March 1, 2014
Completion Date
March 1, 2014
Last Updated
June 28, 2018
NCT07205107
NCT06225570
NCT05891795
NCT06141330
NCT06501560
NCT03883269
Lead Sponsor
Galderma R&D
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions